NICE RECOMMENDATION ON TAXOL

Summary

That this House welcomes the recommendation of the National Institute for Clinical Excellence that the anti-cancer drug Taxol should be available routinely as a first-line treatment for women with ovarian cancer regardless of where they live; notes that as many as one-third of health authorities do not currently fund Taxol for all women who could benefit from it; recognises the financial constraints faced by health authorities; and calls on the Government to ringfence sufficient funding to pay for treatments recommended by NICE, so that patients are no longer denied access to effective drugs on the basis of cost.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 9 May 2000

   Early Day Motion

   That this House welcomes the recommendation of the National Institute for Clinical Excellence that the anti-cancer drug Taxol should be available routinely as a first-line treatment for women with ovarian cancer regardless of where they live; notes that as many as one-third of health authorities do not currently fund Taxol for all women who could benefit from it; recognises the financial constraints faced by health authorities; and calls on the Government to ringfence sufficient funding to pay for treatments recommended by NICE, so that patients are no longer denied access to effective drugs on the basis of cost.

   Source: Early Day Motion

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

• Dame Joan Ruddock · Labour · Primary sponsor

Related records

No cross-record relationships stored yet.